NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Xeltis’ closes €10.5 million Series D financing<
05 Sep 2019

Xeltis’ closes €10.5 million Series D financing

The funding was provided by existing institutional and private investors, including all venture capital funds (VCs) already financing the company.
16 Jul 2019

AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury

AM-Pharma B.V. (‘AM-Pharma, today announces that it has raised €116m [$133m] from a European syndicate of new and existing investors.
Sanifit announces €72.2M ($80.9M) financing in Spain’s largest private biotech fundraise<
26 Jun 2019

Sanifit announces €72.2M ($80.9M) financing in Spain’s largest private biotech fundraise

Proceeds to enable progression of orphan designated lead candidate SNF472 into pivotal phase 3 trial for treatment of calciphylaxis
04 Jun 2019

Rainier Therapeutics Announces Presentation of Patient Biopsy Data Demonstrating Vofatamab’s Ability to Increase Immune Cell Activation

Rainier Therapeutics, Inc., today announced the presentation of data from its FIERCE-22 trial where vofatamab, the company’s lead therapeutic stimulates an increase in immune cell activation in patients with metastatic bladder cancer.
04 Jun 2019

Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia

Minoryx Therapeutics, today announces that the first patient has been dosed with its lead candidate, leriglitazone (MIN-102), in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia.
03 Jun 2019

Rainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder Cancer)

Rainier Therapeutics, Inc., today announced the first interim analysis results from its ongoing FIERCE-22 trial of vofatamab in patients with metastatic bladder cancer.
Aura Biosciences Completes $40 Million Series D Financing<
02 Apr 2019

Aura Biosciences Completes $40 Million Series D Financing

The Company plans to use the proceeds from the Series D financing to support the late stage clinical development of their lead asset, light-activated AU-011.
20 Mar 2019

Pfizer secures exclusive option to acquire gene therapy company vivet therapeutics

Vivet Therapeutics, announced today that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares.
27 Feb 2019

Minoryx Therapeutics receives approval from Spanish Regulatory Agency to initiate phase 2 study in Friedreich’s Ataxia

Minoryx Therapeutics, today announces that it has received approval from the Spanish Agency of Medicines and Medical Devices (AEMPS) to launch a phase 2 clinical trial in Friedreich’s Ataxia with its lead candidate, MIN-102.
15 Jan 2019

Minoryx Therapeutics extends its activities in Belgium

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has created a fully owned subsidiary in Belgium.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.